发布求助
文献互助 智能选刊 最新文献

Idrugs最新文献

筛选
英文 中文
HIV vaccine development: past, present and future. 艾滋病毒疫苗的发展:过去、现在和未来。
Idrugs Pub Date : 2010-12-01
Merlin L Robb
{"title":"HIV vaccine development: past, present and future.","authors":"Merlin L Robb","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The search for an HIV vaccine began following the discovery of the virus more than 25 years ago. Despite important progress, an effective vaccine remains an elusive goal that will likely require many more years of R&D to achieve. Following recent advances in research, however, there has been increased optimism that a prophylactic HIV vaccine is feasible. A consensus is forming among researchers to support a larger role for proof-of-concept efficacy clinical trials, conducted in parallel with invigorated basic research efforts and testing in animal models, to accelerate the discovery of key principles that will guide rational vaccine development.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 12","pages":"852-6"},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29532105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Considerations in vaccine patent protection. 疫苗专利保护的考虑。
Idrugs Pub Date : 2010-12-01
Lorna Brazell
{"title":"Considerations in vaccine patent protection.","authors":"Lorna Brazell","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This feature article discusses the basic principles of patentability as related to vaccine research, and outlines recent cases in the US and EU in which vaccine patents have been considered. Issues regarding eligibility for supplementary protection, as currently being considered by the Court of Justice of the EU, are also outlined, as well as the implications of such issues in protecting future vaccine research.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 12","pages":"885-9"},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29532527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
2010 World Stem Cell Summit--part 2. October 4-6, 2010, Detroit, MI, USA. 2010年世界干细胞峰会——第二部分。2010年10月4日至6日，美国密歇根州底特律。
Idrugs Pub Date : 2010-12-01
Alain Vertès
{"title":"2010 World Stem Cell Summit--part 2. October 4-6, 2010, Detroit, MI, USA.","authors":"Alain Vertès","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The 2010 World Stem Cell Summit, held in Detroit, included topics covering new developments in the field of regenerative medicine. This conference report highlights selected presentations on the cancer stem cell hypothesis, stem cell therapy for amyotrophic lateral sclerosis, GRNOPC-1 for spinal cord injury, the use of cord blood stem cells for spinal cord injury, mesenchymal stem cell research and applications in cardiac therapy, tissue engineering, and very small embryonic-like stem cells. Investigational drugs discussed include NSI-566RSC (Neuralstem) and GRNOPC-1 (Geron Corp).</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 12","pages":"822-4"},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29533182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alzheimer's Disease Drug Discovery--11th International Conference--Promising New Therapeutic Approaches. 27-28 September 2010, Jersey City, NJ, USA. 阿尔茨海默病药物发现-第11届国际会议-有希望的新治疗方法。2010年9月27-28日，泽西城，新泽西州，美国。
Idrugs Pub Date : 2010-12-01
Michael S Wolfe
{"title":"Alzheimer's Disease Drug Discovery--11th International Conference--Promising New Therapeutic Approaches. 27-28 September 2010, Jersey City, NJ, USA.","authors":"Michael S Wolfe","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The 11th Alzheimer's Disease Drug Discovery International Conference, held in Jersey City, NJ, USA, included topics covering new therapeutic developments in the field of Alzheimer's disease. This conference report highlights selected presentations on the use of patient-specific stem cells, and neuroprotection, regeneration and cognitive enhancement strategies for the prevention or treatment of Alzheimer's disease. Investigational approaches discussed include allopregnanolone for neuron protection and regeneration, PDE5 inhibitors as therapeutics, upregulating the protein Klotho to prevent cognitive decline, targeting memory deficits induced by Aβ42 oligomers, inhibiting striatal-enriched protein tyrosine phosphatase (STEP) for treating neuropsychiatric disorders, and agonism of GABA-A receptors to treat age-related cognitive deficits.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 12","pages":"825-7"},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29533183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeted Cancer Therapies World Congress 2010--part 2. 21-23 September 2010, Zurich, Switzerland. 2010年世界癌症靶向治疗大会第二部分。2010年9月21日至23日，瑞士苏黎世。
Idrugs Pub Date : 2010-12-01
Hagop Youssoufian
{"title":"Targeted Cancer Therapies World Congress 2010--part 2. 21-23 September 2010, Zurich, Switzerland.","authors":"Hagop Youssoufian","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The Targeted Cancer Therapies World Congress, held in Zurich, included topics covering new regulatory and therapeutic developments in the field of cancer therapy and accompanying diagnostics. This conference report highlights selected presentations on improving market access, minimizing redundant R&D investment and standardizing cancer biomarkers, incorporating diagnostics into drug development and advances in biomarker discovery for cancer.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 12","pages":"833-5"},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29532100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Accelerating the discovery of new drug targets with chemical proteomics. 利用化学蛋白质组学加速发现新的药物靶点。
Idrugs Pub Date : 2010-12-01
Atwood K Cheung, Rishi K Jain
{"title":"Accelerating the discovery of new drug targets with chemical proteomics.","authors":"Atwood K Cheung,&nbsp;Rishi K Jain","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The application of chemical proteomics to new target discovery can lead to a rapid understanding of disease mechanism and new therapeutic methods. Successful application includes a thorough understanding of SAR and the validation of target relevance using multiple genetic and biochemical methods. This feature review highlights several successful applications of chemical proteomics and outlines the strategy and approaches that lead to the discovery of novel therapeutic targets.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 12","pages":"862-8"},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29532107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease. Florbetapir (18F)，一种PET显像剂，可与淀粉样斑块结合，用于潜在的阿尔茨海默病检测。
Idrugs Pub Date : 2010-12-01
Nobuyuki Okamura, Kazuhiko Yanai
{"title":"Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.","authors":"Nobuyuki Okamura,&nbsp;Kazuhiko Yanai","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Florbetapir (18F), being developed by Avid Radiopharmaceuticals, is an 18F-labeled PET tracer binding to amyloid-β (Aβ) plaques for the potential detection of Alzheimer's disease (AD). Preclinical studies indicated high binding affinity of florbetapir (18F) to Aβ fibrils and specific labeling of Aβ plaques in the cortical regions and hippocampus. In phase I and II clinical trials, florbetapir (18F) clearly differentiated patients with AD from healthy controls and uptake was most prominent in the precuneus. The neocortical-to-cerebellar tracer uptake ratio reached a plateau within 50 min post-injection and high-quality images were acquired with 5 to 10 min image acquisition time with 370 MBq of florbetapir (18F). Results from an ongoing phase III clinical trial confirmed a strong correlation between florbetapir (18F) PET images and postmortem assessment of Aβ deposition. No serious adverse events were reported in any of the clinical trials of florbetapir (18F). At the time of publication, a marketing application for florbetapir (18F) had been submitted to the US FDA. The fast kinetics and strong evidences of radiological-pathological correlation are advantages of florbetapir (18F) over other 18F-labeled amyloid PET tracers. This tracer has a potential to serve as an agent for preclinical detection of AD-related pathology in the large elderly population.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 12","pages":"890-9"},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29532528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeted Cancer Therapies World Congress 2010--part 1. 21-23 September 2010, Zurich, Switzerland. 2010年世界癌症靶向治疗大会-第一部分。2010年9月21日至23日，瑞士苏黎世。
Idrugs Pub Date : 2010-12-01
Hagop Youssoufian
{"title":"Targeted Cancer Therapies World Congress 2010--part 1. 21-23 September 2010, Zurich, Switzerland.","authors":"Hagop Youssoufian","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The Targeted Cancer Therapies World Congress, held in Zurich, included topics covering new developments in the field of cancer therapy. This conference report highlights selected presentations on the global market for targeted cancer therapies, understanding European regulatory evaluation strategies and meeting the requirements for acceptable reimbursement.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 12","pages":"830-2"},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29532099","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances in flavivirus vaccine development. 黄病毒疫苗的研究进展。
Idrugs Pub Date : 2010-12-01
Beth-Ann G Coller, David E Clements, Timothy Martyak, Michele Yelmene, Mike Thorne, D Elliot Parks
{"title":"Advances in flavivirus vaccine development.","authors":"Beth-Ann G Coller,&nbsp;David E Clements,&nbsp;Timothy Martyak,&nbsp;Michele Yelmene,&nbsp;Mike Thorne,&nbsp;D Elliot Parks","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Flaviviruses comprise a diverse family of viruses that are cumulatively responsible for hundreds of millions of cases of infection annually. The Flavivirus genus includes both insect-vectored viruses, such as yellow fever and dengue, and non-vectored viruses such as HCV; the viruses have a broad range of disease presentation and geographic distribution. No specific antiviral therapies are currently available for the diseases caused by insect-vectored flaviviruses. Thus, efforts have been focused on the prevention of disease, through either vaccination or vector control, rather than on the treatment of infected individuals. While vector control can occasionally be successful in controlling the spread of flavivirus outbreaks, vaccines appear to be a more cost-effective, sustainable, and environmentally friendly approach. A review of vaccines for the medically important flaviviruses presents the full spectrum of vaccine options and complexity levels, and provides examples of successes and major challenges. The insect-borne flavivirus vaccine field is dynamic, with new and improved vaccines being advanced to replace existing vaccines, and novel vaccine approaches being developed for those targets that currently lack an approved vaccine. Advances in scientific knowledge and in the application of new technologies are helping to overcome some of the key challenges that have stymied the field for decades. New, safe and effective vaccines to protect against yellow fever, Japanese encephalitis, tick-borne encephalitis, West Nile and dengue viruses will likely result.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 12","pages":"880-4"},"PeriodicalIF":0.0,"publicationDate":"2010-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29532526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Using large-scale RNAi screens to identify novel drug targets for cancer. 使用大规模的RNAi筛选来识别新的癌症药物靶点。
Idrugs Pub Date : 2010-11-01
Jeroen H Nijwening, Roderick L Beijersbergen
{"title":"Using large-scale RNAi screens to identify novel drug targets for cancer.","authors":"Jeroen H Nijwening,&nbsp;Roderick L Beijersbergen","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In recent years, the development and clinical implementation of targeted therapeutics have progressed significantly. The specific inhibition of components of signal transduction pathways controlling proliferation and survival has been a highly successful research strategy. However, cancer is a heterogeneous disease and, even within one type of cancer, different genetic alterations are associated with identical phenotypes. To advance the use of targeted therapeutics, it is not only essential to identify the crucial factors in the signal transduction networks that control cell proliferation and survival, but also to classify individual tumors according to genetic alterations that correlate with pathway activation. RNAi screening technologies have become established as an important strategy both to identify novel targets and to provide novel biomarkers that are crucial for the further development of personalized medicine. This feature review discusses different RNAi screening strategies and their contribution to the rapidly evolving field of targeted therapeutics.</p>","PeriodicalId":55031,"journal":{"name":"Idrugs","volume":"13 11","pages":"772-7"},"PeriodicalIF":0.0,"publicationDate":"2010-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29443248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：604180095
Book学术官方微信